Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.56 |
| ▸ | SCD | O00767 | 2/20 | 0.50 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370042 | 0.86 | CHRM4 (0.53) | CHRM4SCDLMNATHRBALDH1A1 | |
| SCHEMBL3053289 | 0.85 | HPGD (0.57) | CHRM4SCDALDH1A1HPGD | |
| SCHEMBL3371072 | 0.80 | CHRM4 (0.55) | CHRM4SCDSENP1MAPK1RAB9A | |
| SCHEMBL3051517 | 0.79 | HPGD (0.57) | CHRM4RAB9ALMNAALDH1A1HPGD | |
| SCHEMBL7159985 | 0.78 | CHRM4 (0.54) | CHRM4CCR1RAB9ALMNATHRB | |
| SCHEMBL13082534 | 0.76 | CHRM4 (0.62) | CHRM4SCDSENP1RAB9AMAOB | |
| SCHEMBL3371185 | 0.75 | SCD (0.73) | CHRM4SCDMAOB | |
| SCHEMBL3454982 | 0.74 | SCD (0.50) | CHRM4SCDSENP1CCR1MAOB | |
| SCHEMBL12195644 | 0.74 | CCR1 (0.71) | CCR1RAB9ALMNAHPGD | |
| SCHEMBL20804355 | 0.73 | HPGD (0.57) | MAPK1RAB9AALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024583-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-8501746-B2 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| WO-2007143597-A9 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-2029572-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20090156615-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156615-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | CHRM4 3011/4885SCD 1/4885SENP1 2835/4885 |
| US-20140024583-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | CHRM4 3011/4885SCD 1/4885SENP1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.